Valiant Organics Q3 FY26: Profit Up, Debt ₹165cr

Board clears unaudited results after Feb 13 meeting

Valiant Organics Limited informed stock exchanges about the outcome of its Board meeting held on February 13, 2026. The Board reviewed and approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, based on the Audit Committee’s recommendation. The meeting began at 12:45 PM IST and concluded at 04:02 PM IST. The company said the results would be published in newspapers as required under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Extracts of the financial results were published in The Financial Express (English edition) and Mumbai Lakshadeep (Marathi Edition) on February 14, 2026. The detailed results were made available on the company’s website and on the BSE and NSE websites.

Q3 FY26 at a glance: revenue down, profit supported

For the quarter ended December 31, 2025 (Q3 FY26), Valiant Organics reported standalone revenue from operations of ₹159.07 crore. Standalone net profit for the quarter came in at ₹6.06 crore. The company’s operational performance in the quarter showed a revenue decline versus the comparable period, but profitability improved with cost management and exceptional gains mentioned in the company updates around the period.

A separate earnings update also reported that consolidated net profit declined 33.15% to ₹3.65 crore in the December 2025 quarter from ₹5.46 crore a year earlier. The same update said sales declined 14.77% to ₹159.27 crore from ₹186.86 crore. These numbers align closely with the consolidated revenue from operations disclosed for Q3 FY26.

Standalone numbers: quarter and nine-month performance

On a standalone basis, Valiant Organics reported revenue from operations of ₹159.07 crore for Q3 FY26. For the nine months ended December 31, 2025, standalone revenue from operations stood at ₹520.68 crore. Over the nine-month period, standalone net profit was ₹19.24 crore.

The company’s results commentary for the period highlighted that profitability improved even as revenue moderated. It also pointed to operational discipline and the effect of exceptional items booked during the nine months. In addition, the company noted an estimated increase in provision for employee benefits due to the New Labour Codes, effective November 21, 2025.

Consolidated numbers: quarter and nine-month performance

On a consolidated basis, revenue from operations for Q3 FY26 was ₹159.27 crore. Consolidated net profit for the quarter was ₹3.64 crore. For the nine months ended December 31, 2025, consolidated revenue from operations was ₹520.98 crore and net profit was ₹17.51 crore.

Valiant Organics operates as a single segment engaged in the manufacturing chemicals business, as stated in the results-related disclosures. The company also said it had complied with relevant regulatory requirements under Regulations 33 and 30 of the SEBI Listing Regulations for the financial results and disclosures.

Exceptional item linked to Sarigam fire insurance settlement

A key disclosed item for the nine months ended December 31, 2025 was an exceptional item of ₹5.72 crore related to a fire insurance claim settlement for the Sarigam Division fire incident in FY 2022-23. The company reported receipt of ₹8.53 crore towards the settlement. Out of this, ₹5.72 crore was recognised under exceptional items during the period, with the balance accounted for appropriately in the financial statements.

For investors, this distinction matters because exceptional items can lift reported profitability without reflecting underlying operating demand or pricing. The company’s disclosures clearly separated the recognition under exceptional items from the total claim receipts.

Industry backdrop: pricing pressure and China-linked competition

Valiant Organics had earlier faced a demand and pricing challenge. In Q3 FY24, the company saw a 22% decline in revenue, attributed to a global industry slowdown and competitive pricing pressure, particularly from Chinese imports. This context is important because the specialty chemicals sector has periodically seen margin pressure when global supply increases and import prices soften.

The company’s updates around the period also pointed to signs of recovery. Management projected 40% revenue growth for FY25, driven by new product launches and improved market conditions, as cited in the provided information.

Balance sheet snapshot: net debt and equity base

As of December 31, the company reported net debt of approximately ₹165 crore. This number provides a quick indicator of leverage while assessing earnings quality and recovery trends. Separately, the company disclosed paid-up equity capital of ₹28.02 crore (face value ₹10 each).

The company also disclosed ESOP activity: 15,000 shares were allotted on November 29, 2025, and stock options were granted (15,000 on May 22, 2025 and 1,000 on November 13, 2025).

Stock and disclosure timeline

The share price of VALIANTORG was cited at ₹311.55 as on May 11, 2026. The company had also issued a board meeting intimation for February 13, 2026 to consider and approve unaudited Q3 FY2025-26 financials, and noted that the trading window was closed until February 15, 2026.

Key numbers table

Governance updates from the 20th AGM

Valiant Organics held its 20th AGM on September 26, where shareholders approved several resolutions. These included the re-appointment of Shri Mahek M. Chheda as Executive Director and Shri Kiritkumar H. Desai as Non-Executive Director. Shareholders also approved the appointment of M/s Mehta & Mehta as Secretarial Auditor for five years, from FY 2025-26 to FY 2029-30.

The AGM also covered remuneration approvals for the Managing Director and the cost auditor, along with approval for material related party transactions with entities including Aarti Industries Limited and Valiant Laboratories Limited, as mentioned in the company’s AGM-related disclosure summary.

What the disclosures mean for investors

The Q3 FY26 set of numbers shows the company operating in a challenging demand and pricing environment, while reporting profits that were also supported by an insurance-related exceptional item. The net debt figure of about ₹165 crore remains a key monitorable for the market, alongside the trajectory of revenue recovery. The company’s projection of 40% revenue growth for FY25, driven by new products and improved market conditions, indicates management expectations, though the actual outcome will depend on execution and industry pricing.

Conclusion

Valiant Organics’ Board-approved unaudited Q3 FY26 results underline a quarter of lower revenue with reported profits and a clearly disclosed exceptional gain linked to the Sarigam fire insurance settlement. The next set of market-relevant cues will come from subsequent quarterly filings and any further exchange disclosures on demand conditions, product launches, and leverage trends.